Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Trial ID or NCT#
NCT00343694
Status
NOT RECRUITING
Purpose
This phase I/II trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia. Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
Official Title
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Eligibility Criteria
Ages Eligible for Study: 2 Years to 21 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Neyssa Marina
Contact us to find out if this trial is right for you.
Contact
Peds Hem/Onc CRAs
650-723-5535
View on ClinicalTrials.gov
